S.E. Davidson

ORCID: 0000-0001-9435-7438
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Endometrial and Cervical Cancer Treatments
  • Effects of Radiation Exposure
  • Cancer survivorship and care
  • Advanced Radiotherapy Techniques
  • Cervical Cancer and HPV Research
  • Colorectal and Anal Carcinomas
  • Advances in Oncology and Radiotherapy
  • Lung Cancer Treatments and Mutations
  • Ovarian cancer diagnosis and treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Management of metastatic bone disease
  • MRI in cancer diagnosis
  • Lung Cancer Diagnosis and Treatment
  • Cancer, Hypoxia, and Metabolism
  • Prostate Cancer Diagnosis and Treatment
  • Prostate Cancer Treatment and Research
  • Global Cancer Incidence and Screening
  • Palliative Care and End-of-Life Issues
  • Ultrasound and Hyperthermia Applications
  • Gastric Cancer Management and Outcomes
  • Advanced MRI Techniques and Applications
  • Angiogenesis and VEGF in Cancer
  • Clinical practice guidelines implementation
  • Molecular Biology Techniques and Applications
  • Colorectal Cancer Surgical Treatments

The Christie NHS Foundation Trust
2011-2022

The Christie Hospital
2010-2020

Manchester Academic Health Science Centre
2020

Health Innovation Manchester
2020

Heidelberg University
2017

University Hospital Heidelberg
2017

University of Leeds
2016

Engineering Arts (United States)
2016

Southern California Institute of Architecture
2016

University of Manchester
2004-2014

10.5694/j.1326-5377.1964.tb133789.x article EN The Medical Journal of Australia 1964-01-01

The number of patients with chronic gastrointestinal (GI) symptoms after cancer therapies which have a moderate or severe impact on quality life is similar to the diagnosed inflammatory bowel disease annually. However, in contrast disease, most these are not referred for gastroenterological assessment. Clinicians who do see often unaware benefits targeted investigation (which differ from those required exclude recurrent cancer), range available treatments and how pathological processes...

10.1136/gutjnl-2011-300563 article EN cc-by-nc Gut 2011-11-04

Abstract The presence of hypoxia in tumours results the overexpression certain genes, which are controlled via transcription factor HIF‐1. Hypoxic cells known to be radioresistant and chemoresistant, thus, a reliable surrogate marker is desirable ensure that treatment may rationally applied. Recently, HIF‐1‐regulated proteins Glut‐1 CAIX were validated as intrinsic markers by comparison with pO 2 measured using oxygen electrodes. We compare expression binding bioreductive drug pimonidazole....

10.1002/ijc.10904 article EN International Journal of Cancer 2003-01-16

Abstract Objective This study compared the efficacy of a media literacy program and self‐esteem designed to reduce general specific risk factors for eating disorders. Method Four classes 86 grade 8 students (53 boys 33 girls), mean age 13 years, were randomly assigned either control condition or one two intervention conditions. Assessment was carried out at baseline, postintervention 3‐month follow‐up. Results At group had lower scores on weight concern than (p =0.007) but did not. There...

10.1002/eat.10136 article EN International Journal of Eating Disorders 2003-03-20

S1 Using computerized adaptive testing Tim Croudace S2 Well-being: what is it, how does it compare to health and are the implications of using inform policy John Brazier O1 “Am I going get better?”—Using PROMs patients about likely benefit surgery Nils Gutacker, Andrew Street O2 Identifying Patient Reported Outcome Measures for an electronic Personal Health Record Dan Robotham, Samantha Waterman, Diana Rose, Safarina Satkunanathan, Til Wykes O3 Examining change process over time...

10.1186/s12955-016-0540-5 article EN cc-by Health and Quality of Life Outcomes 2016-10-01

Patients treated with standard chemotherapy for metastatic or relapsed cervical cancer respond poorly to conventional (response achieved in 20-30% of patients) an overall survival less than 1 year. High tumour angiogenesis and high concentrations intratumoural VEGF are adverse prognostic features. Cediranib is a potent tyrosine kinase inhibitor VEGFR1, 2, 3. In this trial, we aimed assess the effect addition cediranib carboplatin paclitaxel patients recurrent cancer.

10.1016/s1470-2045(15)00220-x article EN cc-by The Lancet Oncology 2015-10-25

Abstract Purpose: Hypoxia-inducible factor (HIF)-1α expression was studied retrospectively in locally advanced carcinoma of the cervix relation to other methods for measuring/assessing tumor hypoxia and outcome after radiotherapy. Experimental Design: HIF-1α examined formalin-fixed biopsies using a semiquantitative scoring system correlated with measurements obtained oxygen electrodes, pimonidazole staining, carbonic anhydrase 9. Results: High showed weak correlation low pO2 (r = −0.26; P...

10.1158/1078-0432.ccr-03-0135 article EN Clinical Cancer Research 2004-12-15

The Tofts tracer kinetic models are often used to analyze dynamic contrast-enhanced MRI data. They derived from a general two-compartment exchange model (2CXM) but assume negligible plasma mean transit time. 2CXM estimates tissue perfusion and capillary permeability-surface area; the estimate transfer constant Ktrans, which reflects combination of these two parameters. aims this study were compare report microvascular parameters in patients with cervical cancer. Thirty scanned pretreatment...

10.1002/mrm.22217 article EN Magnetic Resonance in Medicine 2010-02-25

To compare survival and late complications between patients treated with chemoradiotherapy radiotherapy for locally advanced cervix cancer.A Royal College of Radiologists' audit in UK cancer centres 2001-2002. Survival, recurrence were assessed grouped according to radical treatment received (radiotherapy, chemoradiotherapy, postoperative or chemoradiotherapy) non-radical treatment. Late complication rates using the Franco-Italian glossary.Data analysed 1243 from 42 centres. Overall 5-year...

10.1016/j.clon.2010.06.002 article EN cc-by Clinical Oncology 2010-07-02
Coming Soon ...